Highlights

  • FY26 revenue declined to AUD 23.573 million from AUD 27.812 million.
  • Profit attributable to owners decreased to AUD 1.177 million from AUD 5.252 million.
  • Net tangible asset backing rose to AUD 0.28 per share from AUD 0.27.

Star Combo Pharma Ltd (ASX:S66) was marked at AUD 0.14, a 0.00% move, after reporting FY26 sales and profit below their prior-year levels. FY26 revenue declined to AUD 23.573 million from AUD 27.812 million. Profit attributable to owners decreased to AUD 1.177 million from AUD 5.252 million. Net tangible asset backing rose to AUD 0.28 per share from AUD 0.27.

Full-Year Revenue Movement

Star Combo Pharma’s audited preliminary final report recorded ordinary revenue of AUD 23,573,050 for the year ended 30 June 2026, compared with AUD 27,811,548 in FY25. The movement was a decline of AUD 4,238,498. The reporting entity includes Star Combo Pharma and its controlled entities, which operate in the health-products manufacturing and distribution business. The results are presented for the 12 months ended 30 June 2026 against the equivalent 2025 period. The company directors’ report and financial statements accompany its Appendix 4E.

Profit Before and After Tax

Profit before tax from ordinary activities attributable to owners was reported as AUD 528,472, versus AUD 5,312,588 in the previous financial year. Profit from ordinary activities attributable to owners amounted to AUD 1,176,626, down from AUD 5,252,342. The decline in reported profit was AUD 4,075,716. The before-tax and attributable-profit amounts are separate measures and should not be combined. The company preliminary final report identifies both periods and amounts, allowing a direct comparison of its reported statutory financial performance.

Tangible Assets and Dividends

Net tangible assets per ordinary security were AUD 0.28 at the FY26 reporting date, compared with AUD 0.27 for FY25. Star Combo Pharma also disclosed that dividends totalling AUD 400,000 were declared during the financial year and provided for in its financial statements. These figures sit alongside, rather than replace, the profit-and-loss information in the report. The Appendix 4E states that the statements and accompanying notes were audited and that there were no audit disputes, with the auditor’s report included in the attached report.

Reporting Scope and Business Activity

Star Combo Pharma develops and manufactures complementary health products, including vitamins and dietary supplements, and participates in branded-product distribution and contract manufacturing. Its reporting arrangements consolidate the parent company and entities controlled during the relevant financial year. Richard Allely signed the preliminary final report as chairman on 25 August 2026. The document also includes the directors’ report, statements and explanatory notes covering the company financial position and transactions. Its FY26 statutory results therefore provide the main factual comparison without relying on unquantified claims about future manufacturing output.